Regulatory Affairs Solutions for Biotech
Assyro AI empowers regulatory affairs professionals in biotechnology companies with intelligent regulatory tools. RA professionals spend 60% of their time on manual drafting, formatting, and regulatory tracking instead of strategic work. Assyro automates the grind so you focus on the decisions that actually move submissions forward.
What Regulatory Affairs Teams Do
- Preparing and submitting regulatory dossiers to health authorities
- Tracking regulatory guidance and policy changes
- Maintaining product registrations and renewals
- Advising on regulatory strategy and pathways
- Coordinating with health authorities on submissions and inquiries
Challenges in Biotech
- 10+ hours per week spent manually tracking regulatory changes across multiple agencies
- Document drafting and formatting consumes 60% of time that should go to strategic work
- Submission timelines and milestones are tracked in spreadsheets that are always outdated
- A 5-person RA team is handling work that used to require a department of 15
- First IND prep takes 8-12 weeks because everything is manual and fragmented
How Assyro AI Helps
- Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- Draft submission documents 14x faster with AI that understands clause-level requirements
- Validate eCTD formatting continuously as your team works, not as a final step
- Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Coordinate CRO deliverables in one workspace with version control and traceable handoffs
Key Skills We Support
- eCTD/CTD expertise
- Health authority interactions
- Regulatory strategy
- Document management
- Cross-functional collaboration
Regulations We Cover
- 21 CFR Part 600
- ICH Q5-Q12
- FDA CBER guidance
- EMA ATMPs
- Biosimilar guidance
Frequently Asked Questions
RA teams using Assyro recover 100+ hours per submission cycle by automating drafting, validation, and regulatory tracking. That's time redirected from manual formatting to strategic regulatory work.
Regulatory Context
Regulatory Affairs teams in Biotech depend on current regulatory intelligence to keep submissions, quality narratives, and inspection responses aligned with health-authority expectations.
Common Mistakes
- Treating submission quality as a final publishing step instead of a continuous process.
- Reusing precedent language without checking current jurisdiction updates.
- Weak linkage between strategy assumptions and dossier evidence.
Key Regulatory Terms
- Electronic Common Technical Document
eCTD is the standard electronic format for pharmaceutical regulatory submissions, organizing CTD content into five modules with a machine-readable backbone so an agency can navigate an application and track every amendment across its lifecycle.
- NDA
A New Drug Application (NDA) is the marketing application a sponsor submits to obtain FDA approval to market a new drug in the United States, carrying the complete safety, effectiveness, manufacturing, and labeling record supporting that decision.
- Investigational New Drug
IND is the FDA application a sponsor submits before shipping or administering an unapproved drug to human subjects, authorizing a clinical investigation rather than granting marketing approval. Studies of a lawfully marketed drug may be exempt.
- Common Technical Document
Common Technical Document is the ICH-harmonized dossier structure that fixes what content belongs in each of five modules of a drug application, letting one technical package serve regulators across the ICH regions.
Relevant Regulatory Intelligence
Related Actions
Other Roles in Biotech
Regulatory Affairs in Other Industries
Ready to Transform Your Regulatory Affairs Operations?
See how Assyro AI can accelerate regulatory work for regulatory affairs professionals in biotechnology companies.
Schedule a Demo